Literature DB >> 3345798

Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol.

L M Mir1, H Banoun, C Paoletti.   

Abstract

The possibility of introducing definite amounts of nonpermeant molecules into electropermeabilized living cells has been approached by quantifying the amounts of Lucifer Yellow (LY; a 457-Da highly fluorescent molecule) and Phytolacca americana (Pokeweed) antiviral protein (PAP; a 30,000-Da ribosome-inactivating protein) retained by the cells after closure of the electric-field-induced transient structures of permeation. Without the electropermeabilization, these two molecules enter the cell only in very small amounts by fluid-phase pinocytosis. Under our experimental conditions, using the NIH 3T3 cells, the intracellular LY concentration can reach a value equivalent to the extracellular concentration and can be regulated by controlling the external concentration. We describe the use of LY in a rapid and efficient test for the determination of the best electrical-shock conditions of other cell lines. After electropermeabilization, PAP is 2 X 10(5) times more cytotoxic. Its toxicity can be detected at external concentrations (10(-11) M) corresponding to less than 10 internalized molecules per electropermeabilized cell. Therefore, after electropermeabilization, the nonpermeant molecules have a direct access to the cytosol and the biological effect of nonpermeant substances can be revealed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3345798     DOI: 10.1016/0014-4827(88)90251-0

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  49 in total

1.  Cytoplasmic molecular delivery with shock waves: importance of impulse.

Authors:  T Kodama; M R Hamblin; A G Doukas
Journal:  Biophys J       Date:  2000-10       Impact factor: 4.033

2.  Gene transfer to intact mesenteric arteries by electroporation.

Authors:  J B Martin; J L Young; J N Benoit; D A Dean
Journal:  J Vasc Res       Date:  2000 Sep-Oct       Impact factor: 1.934

3.  Comparative roles of the cell wall and cell membrane in limiting uptake of xenobiotic molecules by Saccharomyces cerevisiae.

Authors:  Mustapha Aouida; Omar Tounekti; Omrane Belhadj; Lluis M Mir
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

4.  Kinetics of transmembrane transport of small molecules into electropermeabilized cells.

Authors:  Gorazd Pucihar; Tadej Kotnik; Damijan Miklavcic; Justin Teissié
Journal:  Biophys J       Date:  2008-06-06       Impact factor: 4.033

5.  Cell-attached patch clamp study of the electropermeabilization of amphibian cardiac cells.

Authors:  R J O'Neill; L Tung
Journal:  Biophys J       Date:  1991-05       Impact factor: 4.033

Review 6.  Nucleic acids electrotransfer-based gene therapy (electrogenetherapy): past, current, and future.

Authors:  L M Mir
Journal:  Mol Biotechnol       Date:  2009-06-27       Impact factor: 2.695

7.  A quantitative study of electroporation showing a plateau in net molecular transport.

Authors:  M R Prausnitz; B S Lau; C D Milano; S Conner; R Langer; J C Weaver
Journal:  Biophys J       Date:  1993-07       Impact factor: 4.033

Review 8.  Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy.

Authors:  Vicente Muñoz Madero; Gloria Ortega Pérez
Journal:  Clin Transl Oncol       Date:  2011-01       Impact factor: 3.405

9.  Electrochemotherapy significantly inhibits the growth of colon 26 tumors in mice.

Authors:  T Tada; K Matsumoto; H Suzuki
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

10.  Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.

Authors:  M Bosnjak; T Dolinsek; M Cemazar; S Kranjc; T Blagus; B Markelc; M Stimac; J Zavrsnik; U Kamensek; L Heller; C Bouquet; B Turk; G Sersa
Journal:  Gene Ther       Date:  2015-04-09       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.